Official Title: “The Effect of Fluoxetine on Measures of Domestic Violence”

This study will evaluate whether fluoxetine (Prozac), used together with traditional psychotherapy, can reduce aggression in people who are physically violent towards their spouses or significant others. Treatment for domestic violence has centered on behavioral therapies, such as anger management and self-control exercises. Recent studies have shown that fluoxetine-a drug commonly used to treat depression and panic disorder-can decrease acts of aggression.

Men and women between the ages of 18 and 65 who have a history of inflicting physical aggression on a spouses or significant others in the past year (with at least one episode occurring not under the influence of alcohol) may be eligible for this study. Participants spouses or significant others will also be asked to participate. All potential participants will be screened with a medical and psychiatric evaluation and history, breath alcohol analysis, blood tests, urine drug screen and electrocardiogram.

Those enrolled will undergo the following procedures:

Perpetrator - Interview and questionnaires - Participants will be interviewed by a social worker about past and current mental health and use of alcohol and illicit drugs and will complete questionnaires assessing emotional state and personality, depression, anxiety, aggression and alcohol consumption. Some of the questionnaires will be repeated at monthly intervals. - Physical performance testing - Performance and speed will be measured in three separate training sessions that involve repeatedly pressing a button on a button box console, earning points worth money. - Dyadic interaction paradigm - Participants will interact with their spouse/significant other in a small room, first discussing a neutral topic, such as the day's events, and then a subject that has been a source of conflict. - Fluoxetine administration - Participants will be randomly assigned to receive either 10 mg. of fluoxetine or placebo (identical capsules with no active ingredients) once a day for 3 days, then twice a day, increasing up to four capsules a day if there are no serious side effects. Blood will be drawn once a month to measure drug levels. At the end of 3 months, participants taking placebo may remain in the study and receive fluoxetine. - Clinic visits - Participants are followed in the clinic weekly for the first month, then twice a month for the next 2 months for adjustment of number of pills, evaluation of aggressive behavior and alcohol...

Study Type: Interventional

Study Design: Treatment

There are no controlled studies assessing the effectiveness of pharmacological interventions to decrease aggression in perpetrators of domestic violence.

Since serotonin reuptake inhibitors (SSRI) have been shown to decrease aggression in other patient populations, we will examine the effectiveness of SSRIs in reducing aggression in perpetrators of domestic violence. In this protocol, perpetrators of domestic violence will be randomized according to a double-blind design to receive either the SSRI, fluoxetine, or placebo. All participants will receive psychotherapy. All participants will also be carefully monitored in the outpatient clinic on a regular basis for three months. Drug efficacy will be established using validated rating scales and provocative aggression inducing paradigms.

Intervention(s) in this Clinical Trial

• Drug: Fluoxetine
  • N/A

INCLUSION CRITERIA:

Men and women over the age of 18 will be eligible for the study if they have:

• A history of at least two episodes of physical aggression (i.e., hitting, pushing, punching, choking etc.) toward their spouse or significant other in the past year;
• A history of at least one episode of physical aggression toward their spouse or significant other which occurred when the perpetrator had not used alcohol/drugs for at least a day;
• A score of at least 3 on the Straus Conflict Tactics physical violence subscale;
• A signed informed consent for participation in the protocol; and
• Agreed to provide investigators with phone numbers of family and/or friends who will be able to provide information about the perpetrators' whereabouts in the event that the perpetrator does not come to appointments.

EXCLUSION CRITERIA:

• Participants under the age of 18 will be excluded from the protocol because the generalizability of the results could potentially be compromised;
• Abnormal laboratory or diagnostic tests which are judged to be clinically significant;
• History of schizophrenia or bipolar disorder;
• Participants judged to be a significant suicide/homicide risk;
• Head trauma resulting in a period of unconsciousness lasting longer than one hour;
• Documented seizure disorder (alcohol withdrawal seizures are not exclusionary);
• History of a major medical problem (i.e., diabetes, cancer);
• Women with a positive pregnancy test or women of childbearing age who are not willing to use some form of birth control during the study;
• Participants whose spouse/significant other is pregnant;
• Participants using an SSRI on a regular basis in the last three months;
• Participants requiring other psychotropic medications;
• Perpetrators requiring medications that inhibit CYP2D6, and could potentially interact with fluoxetine;
• Individuals who are unwilling to forgo access to guns for the duration of the study;
• Participants who are very controlling and are currently stalking their partner;
• Participants who engage in forced sex;
• Participants whose spouse/significant other feel that they are in great danger; and
• Participants participating in the functional MRI paradigm will be excluded if they have ferromagnetic objects in their bodies which might be aversely affected by MRI (e.g., surgical clips; metal fragments in or near brain, eye, or blood vessels; cardiac or neurological pacemaker; cochlear or eye implant).

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00011765

Study ID Number: 010098

ClinicalTrials.gov Identifier: NCT00011765

Health Authority: United States: Federal Government

NIH Clinical Center Detailed Web Page